Condition (MeSH)
Corynebacterium Infections
ClinicalTrials.gov lists 255 trials for Corynebacterium Infections or a narrower condition beneath it. GlaxoSmithKline has the most among industry and government lead sponsors, with 97.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 of the 255 trials are tagged with Corynebacterium Infections itself; the rest are tagged with a narrower condition beneath it.
When did Corynebacterium Infections trials start? (30)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 33
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 4 |
| 2024 | 6 |
| 2023 | 6 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 3 |
| 2019 | 9 |
| 2018 | 7 |
| 2017 | 3 |
Showing 10 of 30 earlier years.
No forecast is made for this condition: it averages 4.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 20 months from start to primary completion across 11 trials still running at the 2026-10-09 snapshot; registered median of 13 months across 210 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Corynebacterium Infections trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 11 |
| Phase 1/2 | 4 |
| Phase 2 | 26 |
| Phase 2/3 | 3 |
| Phase 3 | 122 |
| Phase 4 | 55 |
| Not applicable | 11 |
| Observational | 23 |
How many Corynebacterium Infections trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 6 |
| Active, not recruiting | 6 |
| Completed | 219 |
| Terminated | 3 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Corynebacterium Infections trials? (14)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| GlaxoSmithKline | 97 |
| Sanofi Pasteur, a Sanofi Company | 58 |
| Sanofi | 18 |
| CanSino Biologics Inc. | 7 |
| LG Chem | 7 |
Showing 5 of 14 sponsors.
Which drugs are being tested for Corynebacterium Infections? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| HIBERIX™ | 6 |
| MENJUGATE | 5 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| BOOSTRIX | 19 |
| InfanrixTM hexa | 18 |
| Infanrix IPV Hib | 8 |
| INFANRIX | 6 |
| Prevenar 13 | 5 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Corynebacterium Infections trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Bronchiolitis | 299 | 25 |
| Gastroenteritis | 218 | 41 |
| Pneumonia | 169 | 45 |
| Febrile convulsion | 90 | 22 |
| Upper respiratory tract infection | 75 | 14 |
Showing 5 of 10 adverse events.
Which publications cover Corynebacterium Infections? (13)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Genomic characterization of the <i>C. tuberculostearicum</i> species complex, a prominent member of the human skin microbiome. | mSystems | 2023 | Yes |
| Pitted keratolysis. | Anais brasileiros de dermatologia | 2016 | Yes |
| Analysis of the chronic wound microbiota of 2,963 patients by 16S rDNA pyrosequencing. | Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society | 2016 | Yes |
| Clonal multidrug-resistant Corynebacterium striatum within a nosocomial environment, Rio de Janeiro, Brazil. | Memorias do Instituto Oswaldo Cruz | 2013 | Yes |
| Pitted keratolysis. | Indian journal of dermatology, venereology and leprology | 2005 | Yes |
Showing 5 of 13 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.